Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction
Autor: | Ihab Attia, Hazem Khamis, Ahmed Elkersh, Atef Elbahry, Osama Sanad, Elsayed Farag, Ashraf Reda, Ahmed Bendary, Ahmed Shawky Elserafy, Nabil Farag, Mohammed Selim, Tamer Mostafa, Emad R. Issak |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Renal function chemistry.chemical_compound Diabetes mellitus Internal medicine medicine Empagliflozin Humans Pharmacology (medical) Dapagliflozin Biology Sodium-Glucose Transporter 2 Inhibitors Heart Failure Ejection fraction business.industry Type 2 Diabetes Mellitus Stroke Volume General Medicine Atherosclerosis medicine.disease Diabetes Mellitus Type 2 chemistry Current Opinion Heart failure Sodium/Glucose Cotransporter 2 Cardiology Egypt business |
Zdroj: | Clinical Drug Investigation |
ISSN: | 1179-1918 1173-2563 |
Popis: | Heart failure (HF) is a common cause of cardiovascular mortality and morbidity. Despite advances in treatment, the prognosis remains poor. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors decrease HF events by 27–39% in high-risk patients with type 2 diabetes mellitus (T2DM). Moreover, the DAPA-HF and EMPEROR-Reduced studies randomized patients with HF with reduced ejection fraction (HFrEF) with or without diabetes mellitus to receive guideline-directed medical therapy versus guideline-directed medical therapy plus an SGLT-2 inhibitor. Both studies showed the benefits of SGLT-2 inhibitors. In addition, SGLT-2 inhibitors have shown improvement according to the EMPEROR-Preserved study of HF with preserved ejection fraction (HFpEF). Therefore, a panel of cardiology experts from the Egyptian Atherosclerosis and Vascular Biology Association (EAVA) revised the literature for SGLT-2 inhibitors in HF, along with the recommended indications and contraindications, and this article presents their consensus on the topic. The panel concluded that SGLT-2 inhibitors have significantly benefited patients with chronic HFrEF, as indicated through the DAPA-HF and EMPEROR-Reduced trials. The panel recommended early use of dapagliflozin 10 mg or empagliflozin 10 mg in patients with symptomatic chronic HFrEF, whether diabetic or non-diabetic, to ameliorate HF hospitalization rate, mortality, symptoms, and decline in renal function. |
Databáze: | OpenAIRE |
Externí odkaz: |